Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Mr. Trump sat down with our reporters for an interview in which he talked about his health, watched a video of an ICE shooting and mused about his power on the world stage. Published Jan. 8, ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Getting ready for a Python interview in 2025? It can feel like a lot, trying to remember all the details. Whether you’re just starting out or have been coding for a while, brushing up on common ...

Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence. December 8, 2025 Recursion Pharma's ...

Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, recently sold a significant chunk of his company's common stock. The CEO of Recursion Pharmaceuticals recently disposed of 120 ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...